All practitioners who have a current DEA registration that includes Schedule III authority, may now prescribe buprenorphine for Opioid Use Disorder in their practice if permitted by applicable state law and SAMHSA encourages them to do so. SAMHSA and DEA are actively working on implementation of a separate provision of the Omnibus related to training requirements for DEA registration that becomes effective in June 2023.
Waiver not needed, but training is!
This free four-hour training is for providers who wish to gain the skills and confidence to prescribe buprenorphine for the treatment of opioid use disorder (OUD). While providers are NO LONGER required to obtain a waiver to prescribe buprenorphine for OUD, we will continue to offer trainings so that providers will have the knowledge, skills, and confidence needed to successfully prescribe buprenorphine for OUD. This training will empower prescribers to provide lifesaving treatment to patients with OUD.
We will need at least 3 RSVP’s in order to hold the training.